Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:600750's EV-to-FCF is ranked worse than 59.43% of 557
companies
in the Drug Manufacturers industry
Industry Median: 20.8
vs SHSE:600750: 28.44
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
China Resources Jiangzhong Pharmaceutical Co's PE Ratio (TTM) for today is calculated as:
China Resources Jiangzhong Pharmaceutical Co's share price for today is ¥24.62.
China Resources Jiangzhong Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1.440.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
China Resources Jiangzhong Pharmaceutical Co EV-to-FCF Related Terms
China Resources Jiangzhong Pharmaceutical Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Jiangzhong Pharmaceutical Co EV-to-FCF Chart
China Resources Jiangzhong Pharmaceutical Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Jiangzhong Pharmaceutical Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Jiangzhong Pharmaceutical Co EV-to-FCF vs Drug Manufacturers Industry
China Resources Jiangzhong Pharmaceutical Co's current Enterprise Value is ¥15,416 Mil.
China Resources Jiangzhong Pharmaceutical Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥542 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) has a EV-to-FCF of 28.44 as of Aug. 22, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on China Resources Jiangzhong Pharmaceutical Co and its competitors. This is 77% above median its historical median of 16.08. According to the industry distribution chart, China Resources Jiangzhong Pharmaceutical Co ranks #331 out of 557 companies in the Drug Manufacturers industry, placing it in the top 59.4%.
Is China Resources Jiangzhong Pharmaceutical Co's EV-to-FCF too high?
China Resources Jiangzhong Pharmaceutical Co's current EV-to-FCF of 28.44 is 77% above median its 10-year median of 16.08. The Drug Manufacturers industry median EV-to-FCF is 20.80. China Resources Jiangzhong Pharmaceutical Co's value of 28.44 is 36.7% above this industry median. Based on the distribution chart, China Resources Jiangzhong Pharmaceutical Co ranks #331 out of 557 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, China Resources Jiangzhong Pharmaceutical Co has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Jiangzhong Pharmaceutical Co's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Resources Jiangzhong Pharmaceutical Co ranks #331 out of 557 companies for EV-to-FCF. This places China Resources Jiangzhong Pharmaceutical Co in the lower half of its industry. The industry median EV-to-FCF is 20.80. China Resources Jiangzhong Pharmaceutical Co's value of 28.44 is 36.7% above this benchmark. While the company's 10-year median is 16.08 vs. the industry median of 20.80, China Resources Jiangzhong Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.80, based on 557 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Jiangzhong Pharmaceutical Co's current EV-to-FCF of 28.44 is 36.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on China Resources Jiangzhong Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Jiangzhong Pharmaceutical Co's current EV-to-FCF is 28.44, which is 77% above median its own 10-year median of 16.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Jiangzhong Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥21.52, compared to a current price of ¥24.62 — trading 14.4% above its estimated fair value. The current EV-to-FCF is 28.44, which is 77% above median its 10-year median of 16.08 and 36.7% above the Drug Manufacturers industry median of 20.80. China Resources Jiangzhong Pharmaceutical Co's overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For China Resources Jiangzhong Pharmaceutical Co (SHSE:600750), the current EV-to-FCF is 28.44 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Jiangzhong Pharmaceutical Co (SHSE:600750) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Jiangzhong Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥24.62 is trading 14.4% above its estimated GF Value™ of ¥21.52.
GuruFocus considers China Resources Jiangzhong Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SHSE:600750:
EV-to-FCF: 28.44 (77% above median its 10-year median of 16.08)
GF Value™: ¥21.52 vs. price of ¥24.62 (14.4% above fair value)
Industry Position: 36.7% above the Drug Manufacturers median (#331 of 557)
No single metric tells the full story. See the SHSE:600750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Jiangzhong Pharmaceutical Co Ltd is engaged in the research and development, production, and sale of over-the-counter pharmaceuticals and health-related products, including functional foods. Its business activities also include the production and sale of proprietary Chinese medicines and chemical drugs.
87GF Score
Get the complete analysis for SHSE:600750
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600750 has been successfully added to your 
